🚀 VC round data is live in beta, check it out!
Fate Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Fate Therapeutics and similar public comparables like Kalaris Therapeutics, Prelude Therapeutics, ProQR Therapeutics, Panion & Bf Biotech and more.
Fate Therapeutics Overview
About Fate Therapeutics
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Founded
2007
HQ
Employees
181
Website
Sectors
Financials (LTM)
EV
$43M
Fate Therapeutics Financials
Fate Therapeutics reported last 12-month revenue of $6M and negative EBITDA of ($137M).
In the same LTM period, Fate Therapeutics generated $6M in gross profit, ($137M) in EBITDA losses, and had net loss of ($138M).
Revenue (LTM)
Fate Therapeutics P&L
In the most recent fiscal year, Fate Therapeutics reported revenue of $7M and EBITDA of ($135M).
Fate Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $6M | XXX | $7M | XXX | XXX | XXX |
| Gross Profit | $6M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($137M) | XXX | ($135M) | XXX | XXX | XXX |
| EBITDA Margin | (2107%) | XXX | (2028%) | XXX | XXX | XXX |
| EBIT Margin | (2289%) | XXX | (2222%) | XXX | XXX | XXX |
| Net Profit | ($138M) | XXX | ($136M) | XXX | XXX | XXX |
| Net Margin | (2131%) | XXX | (2051%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Fate Therapeutics Stock Performance
Fate Therapeutics has current market cap of $169M, and enterprise value of $43M.
Market Cap Evolution
Fate Therapeutics' stock price is $1.45.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $43M | $169M | 0.0% | XXX | XXX | XXX | $-1.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialFate Therapeutics Valuation Multiples
Fate Therapeutics trades at 6.6x EV/Revenue multiple, and (0.3x) EV/EBITDA.
EV / Revenue (LTM)
Fate Therapeutics Financial Valuation Multiples
As of March 18, 2026, Fate Therapeutics has market cap of $169M and EV of $43M.
Equity research analysts estimate Fate Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fate Therapeutics has a P/E ratio of (1.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $169M | XXX | $169M | XXX | XXX | XXX |
| EV (current) | $43M | XXX | $43M | XXX | XXX | XXX |
| EV/Revenue | 6.6x | XXX | 6.4x | XXX | XXX | XXX |
| EV/EBITDA | (0.3x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/EBIT | (0.3x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 6.6x | XXX | — | XXX | XXX | XXX |
| P/E | (1.2x) | XXX | (1.2x) | XXX | XXX | XXX |
| EV/FCF | (0.4x) | XXX | (0.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Fate Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Fate Therapeutics Margins & Growth Rates
Fate Therapeutics' revenue in the last 12 month declined by (10%).
Fate Therapeutics' revenue per employee in the last FY averaged $0.0M.
Fate Therapeutics' rule of 40 is (2116%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fate Therapeutics' rule of X is (2131%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Fate Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (10%) | XXX | (12%) | XXX | XXX | XXX |
| EBITDA Margin | (2107%) | XXX | (2028%) | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (2116%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (2131%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 699% | XXX | 700% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1669% | XXX | 1623% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 2322% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Fate Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kalaris Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Prelude Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| ProQR Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Panion & Bf Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Biomm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fate Therapeutics M&A Activity
Fate Therapeutics acquired XXX companies to date.
Last acquisition by Fate Therapeutics was on XXXXXXXX, XXXXX. Fate Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Fate Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialFate Therapeutics Investment Activity
Fate Therapeutics invested in XXX companies to date.
Fate Therapeutics made its latest investment on XXXXXXXX, XXXXX. Fate Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Fate Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Fate Therapeutics
| When was Fate Therapeutics founded? | Fate Therapeutics was founded in 2007. |
| Where is Fate Therapeutics headquartered? | Fate Therapeutics is headquartered in United States. |
| How many employees does Fate Therapeutics have? | As of today, Fate Therapeutics has over 181 employees. |
| Who is the CEO of Fate Therapeutics? | Fate Therapeutics' CEO is Bahram Valamehr. |
| Is Fate Therapeutics publicly listed? | Yes, Fate Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Fate Therapeutics? | Fate Therapeutics trades under FATE ticker. |
| When did Fate Therapeutics go public? | Fate Therapeutics went public in 2013. |
| Who are competitors of Fate Therapeutics? | Fate Therapeutics main competitors are Kalaris Therapeutics, Prelude Therapeutics, ProQR Therapeutics, Panion & Bf Biotech. |
| What is the current market cap of Fate Therapeutics? | Fate Therapeutics' current market cap is $169M. |
| What is the current revenue of Fate Therapeutics? | Fate Therapeutics' last 12 months revenue is $6M. |
| What is the current revenue growth of Fate Therapeutics? | Fate Therapeutics revenue growth (NTM/LTM) is (10%). |
| What is the current EV/Revenue multiple of Fate Therapeutics? | Current revenue multiple of Fate Therapeutics is 6.6x. |
| Is Fate Therapeutics profitable? | No, Fate Therapeutics is not profitable. |
| What is the current EBITDA of Fate Therapeutics? | Fate Therapeutics has negative EBITDA and is not profitable. |
| What is Fate Therapeutics' EBITDA margin? | Fate Therapeutics' last 12 months EBITDA margin is (2107%). |
| What is the current EV/EBITDA multiple of Fate Therapeutics? | Current EBITDA multiple of Fate Therapeutics is (0.3x). |
| What is the current FCF of Fate Therapeutics? | Fate Therapeutics' last 12 months FCF is ($103M). |
| What is Fate Therapeutics' FCF margin? | Fate Therapeutics' last 12 months FCF margin is (1586%). |
| What is the current EV/FCF multiple of Fate Therapeutics? | Current FCF multiple of Fate Therapeutics is (0.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.